March Is Multiple Myeloma Month. In recognition of this important month, join us for a Precision Key Opinion Leader (KOL) Insights series webinar. You’ll hear from two leading investigators on the lessons learned, current trends, and insights relevant to the Multiple Myeloma (MM) US and EU research community. Dr. Paul Richardson and Dr. Maria-Victoria Mateos have collectively published >700 papers and both have been recognized for excellence in MM research. This is a rare opportunity to get a look into current MM treatment.

Join Precision for Medicine and our guest KOL speakers for this important discussion. We look forward to sharing insights important to the MM communities on both sides of the Atlantic. Submit a question to our speakers prior to the event by using the questions box included in your registration submission.

Featured Speakers

Dr. Paul G. Richardson, MD

Clinical Program Leader and Director of Clinical Research
Jerome Lipper Myeloma Center at the Dana-Faber Cancer Institute

Dr. Paul G. Richardson, MD, is Clinical Program Leader and Director of Clinical Research for the Jerome Lipper Myeloma Center at the Dana-Faber Cancer Institute. He has led the clinical development of numerous novel drugs including bortezomib, lenalidomide, pomalidomide, ixazomib, panobinostat, elotuzumab, daratumumab, selinexor, isatuximab, and most recently melflufen, as well as providing a supporting role in the development of Blenrep for the treatment of MM. He has received numerous awards relating to clinical research and patient care while authoring or co-authoring more than 440 original articles and 360 chapters, commentaries, and reviews.

Dr. María-Victoria Mateos, MD, PhD

Consultant Physician in the Haematology Department and Associate Professor of Medicine
University of Salamanca, Spain

Dr. María-Victoria Mateos, MD, PhD, is Consultant Physician in the Haematology Department and Associate Professor of Medicine at the University of Salamanca, Spain. As the Director of the Myeloma Program, she also coordinates the Clinical Trials Unit in Salamanca’s University Hospital Haematology Department while serving as the Coordinator of GEM (the Spanish Myeloma Group). Dr. Mateos has more than 250 published papers and was the recipient of the Birand Durie Award in 2019, recognizing excellence in myeloma research.

Dr. Al Blunt, MD

Senior Vice President for Medical Affairs
Precision for Medicine

Dr. Al Blunt, MD is Senior Vice President for Medical Affairs with Precision for Medicine. Dr Blunt is an oncologist with extensive industry experience conducting first-in-human through to pivotal phase III trials in Multiple Myeloma as well as numerous other oncology indications. Through his role with Precision for Medicine, Dr Blunt supports our sponsors on clinical trial design strategy and execution as well as serving in a consulting capacity offering medical and regulatory guidance to biopharmaceutical clients and regulators.

Leah Tasca

Vice President of Project Management
Precision for Medicine

Leah Tasca, is Vice President of Project Management, North America for Precision for Medicine. Ms. Tasca has experience working with a multitude of oncology treatments including biologics, monoclonal antibodies, chemotherapies, and stem cell transplants. Ms. Tasca has been involved or managed numerous oncology trials which resulted in approval of four drug treatments for multiple myeloma.  Most recently, she has led a Phase II multiple myeloma trial that has resulted in an accelerated submission to the FDA.


Register now for this webinar